Denmark – Pharmaceutical products – Amgros 2027 1.355.a

Opportunity description

Amgros I/S (Amgros) is a partnership with the 5 regions as partners. Amgros wishes to enter into framework agreements for the medicinal products listed in the individual lots below, with a view to supplying the partners’ hospital pharmacies with medicinal products and potentially reselling them to the Faroe Islands and Greenland. Amgros resells the medicinal products to the hospital pharmacies at Amgros’ purchase price plus a surcharge. The framework agreements are non-exclusive. The framework agreements are entered into without any purchase obligation, and the hospital pharmacies in the regions are not obliged to use Amgros’ framework agreements. The tender number (lot) covers the following medicinal products: ATC Code: D11AH08 · Generic name: Abrocitinib · Dosage form: film-coated tablets · Strength: 50 mg · Unit value: 0.15 g · Quantity in units: 468 ··· ATC Code: D11AH08 · Generic name: Abrocitinib · Dosage form: film-coated tablets · Strength: 100 mg · Unit value: 0.15 g · Quantity in units: 7470 ··· ATC Code: D11AH08 · Generic name: Abrocitinib · Dosage form: film-coated tablets · Strength: 200 mg · Unit value: 0.15 g · Quantity in units: 37065. Each tender number is considered an independent lot and is tendered independently of the other tender numbers. A supplier may therefore choose to submit a tender for one, several or all tender numbers, and the award is made separately for each individual tender number. A supplier may therefore be awarded one, several or all lots. Reference is made to the tender conditions, including regarding the submission of tenders under the individual tender numbers. Under the designation "quantity in units" above, an estimated consumption of the medicinal products under the tender number is stated, but actual consumption may differ significantly therefrom. Suppliers must take this into account. The reason for this is that these are medicinal products for treating patients at public hospitals, where the patient’s needs must be met. Furthermore, the medicinal products put out to tender are covered by one or more recommendations and/or treatment guidelines from the Danish Medicines Council, and the consumption of the various medicinal products may be significantly affected thereby. For a more detailed description, reference is made to the tender conditions and the framework agreement. The maximum value of the lot stated below under section 5.1.5 is calculated as a share of 100% of the estimated total value of all lots stated in section 2.1.3. This is because all the medicinal products put out to tender are covered by one or more recommendations and/or treatment guidelines from the Danish Medicines Council, which assesses which of the medicinal products put out to tender are recommended for treating various patient populations, potentially such that certain medicinal products are regarded as equivalent possible first choices, recommended for use in order of priority or the like. The Danish Medicines Council’s assessment may therefore have a significant bearing on which of the medicinal products put out to tender are used within various therapeutic areas and patient populations, and the consumption of the individual medicinal products may also depend on applicable contract prices. This means that, at the time of the tender, it is not possible to estimate which medicinal products will primarily be used during the term of the framework agreement, and it is possible that the use of the medicinal products may change significantly during the term of the framework agreements, including in particular upon the approval of new indications for the individual medicinal products, changed treatment of one or more patient populations and the like. The purpose of setting the maximum value of the individual lots as a share of the total estimated quantity of all lots is to ensure that each of the framework agreements entered into can be used for the necessary procurement. The maximum value has thus been set on the basis of a professional assessment of the potential use of the medicinal products, taking into account the special circumstances relating to the use of medicinal products at public hospitals and the significant bearing that the Danish Medicines Council’s recommendation and/or treatment guideline may have on the actual consumption of the individual medicinal products, including significant changes in the consumption of the various medicinal products. Procedure: open. Estimated value: 32,500,000 DKK. Review the original TED notice for the complete requirement, lots, amendments and attachments.